Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael F. Mahoney
- Full Time Employees
- 53,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
'Selling Winners, Buying Losers': Tech Stocks Drop as Energy Jumps to Start H2
Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
Boston Scientific: The Time Has Come To Catch This Falling Knife
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One
Belo Sun Announces Management Transition
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Why These Three Big Buybacks Are Sending Very Different Signals to Investors
Belo Sun Announces Corporate Update
Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript